Transcode Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Transcode Therapeutics, Inc. (Nasdaq: RNAZ) on July 16, 2026. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Boston, Massachusetts. The report details a material modification to the rights of securityholders regarding the Company's Series C Non-Voting Convertible Preferred Stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure amendments rather than financial performance results.
Material Changes
On July 16, 2026, the Company filed an Amended and Restated Certificate of Designation for its Series C Non-Voting Convertible Preferred Stock. This action was taken following the consent of a majority of Series C holders and approval by the Board of Directors. The primary material change includes:
- Beneficial Ownership Limitation: Increased from 4.99% to 9.99% for holders of Series C Preferred Stock.
- Administrative Corrections: Inclusion of non-substantive revisions to correct scrivener's errors in the prior certificate.
- No New Issuance: No additional securities were issued or sold in connection with this filing.
This amendment relates to the Exclusive Licensing Agreement and Equity Issuance and Registration Rights Agreement previously entered into with Unleash Immuno Oncolytics, Inc. on March 2, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are disclosed beyond the standard incorporation by reference of the full text of the Amended and Restated Certificate of Designation (Exhibit 3.1).
Key Facts for Investor Verification
- Verify the full text of the Amended and Restated Certificate of Designation (Exhibit 3.1) to confirm the exact terms of the 9.99% beneficial ownership limitation.
- Confirm the impact of the increased ownership cap on the Company's relationship with Unleash Immuno Oncolytics, Inc.
- Review the original March 2, 2026 agreements to understand the context of the Series C Preferred Stock issuance.